首页> 美国卫生研究院文献>other >A Phase I trial and PK Study of Cediranib (AZD2171) an Orally Bioavailable Pan-VEGFR Inhibitor in Children with Recurrent or Refractory Primary CNS Tumors

【2h】

A Phase I trial and PK Study of Cediranib (AZD2171) an Orally Bioavailable Pan-VEGFR Inhibitor in Children with Recurrent or Refractory Primary CNS Tumors

机译：复发或难治性原发性中枢神经系统肿瘤儿童口服生物可利用的泛-VEGFR抑制剂塞地尼布（AZD2171）的I期试验和PK研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundCediranib (AZD2171), an oral, pan VEGF inhibitor, was evaluated in this phase I study to determine its toxicity profile, dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics, in children and adolescents with recurrent or refractory primary central nervous system (CNS) tumors.

机译：背景在第一阶段的研究中对口服泛泛VEGF抑制剂塞地拉尼（AZD2171）进行了评估，以确定其毒性特征，剂量限制性毒性（DLT），最大耐受剂量（MTD），药代动力学和药效学在儿童和青少年中的应用。患有复发性或难治性原发性中枢神经系统（CNS）肿瘤。

著录项

期刊名称 other
作者
Mark W. Kieran; Susan Chi; Stewart Goldman; Arzu Onar-Thomas; Tina Young Poussaint; Sridhar Vajapeyam; Frederic Fahey; Shengjie Wu; David C. Turner; Clinton F. Stewart; Marsha Moses; Roger J. Packer; Regina Jakacki; Anu Banerjee; James M. Boyett; Maryam Fouladi; Larry Kun;
展开▼
作者单位

展开▼
年(卷),期 -1(31),9
年度 -1
页码 1433–1445
总页数 24
原文格式 PDF
正文语种
中图分类
关键词
AZD2171 Recentin Cediranib antiangiogenesis Pediatric Brain Tumor;

机译：AZD2171;Recentin;西地尼布;抗血管生成;小儿脑肿瘤;

相似文献

外文文献
中文文献
专利

1. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors [J] . Kieran Mark W., Chi Susan, Goldman Stewart, Child's nervous system: ChNS : official journal of the International Society for Pediatric Neurosurgery . 2015,第9期

机译：复发性或难治性原发性中枢神经系统肿瘤患儿西地尼布（AZD2171）（口服生物可用的pan-VEGFR抑制剂）的I期试验和PK研究
2. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. [J] . Fox E, Aplenc R, Bagatell R, Journal of Clinical Oncology . 2010,第35期

机译：西地那尼（一种口服生物可利用的泛血管内皮生长因子受体抑制剂）在患有顽固性实体瘤的儿童和青少年中的一项1期试验和药代动力学研究。
3. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group [J] . Chuk Meredith K., Widemann Brigitte C., Minard Charles G., Pediatric blood & cancer . 2018,第8期

机译：在患有复发或难治性实体肿瘤的儿童和青少年中的Cabozantib阶段研究，包括CNS肿瘤：试验Advl1211，来自儿童肿瘤组的报告
4. CNX-774, an Irreversible, Selective and Orally Bioavailable Inhibitor of Bruton's Tyrosine Kinase: In Vitro ADME, Selectivity, and Pharmacokinetic Properties [C] . Prasoon Chaturvedi, Matthew Labenski, Erica Evans, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：CNX-774，Bruton的酪氨酸激酶的不可逆转，选择性和口服生物可利用的抑制剂：体外Adme，选择性和药代动力学性能
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. A Phase 1 Trial and Pharmacokinetic Study of Cediranib an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor in Children and Adolescents With Refractory Solid Tumors [O] . Elizabeth Fox, Richard Aplenc, Rochelle Bagatell, -1

机译：Cediranib（一种口服生物利用性泛血管内皮生长因子受体抑制剂）在难治性实体瘤儿童和青少年中的1期试验和药代动力学研究。
7. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors [O] . Mark W. Kieran, Susan Chi, Stewart Goldman, 2015

机译：Cediranib（AZD2171），口服生物可利用的Pan-VEGFR抑制剂的I阶段试验和PK研究，患有复发或难治性原发性CNS肿瘤的儿童

A Phase I trial and PK Study of Cediranib (AZD2171) an Orally Bioavailable Pan-VEGFR Inhibitor in Children with Recurrent or Refractory Primary CNS Tumors

摘要

著录项

相似文献

相关主题

期刊订阅